S W Kang

Chungnam National University Hospital, Sŏul, Seoul, South Korea

Are you S W Kang?

Claim your profile

Publications (12)73.49 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Long-term use of glucocorticoids (GC) is problematic for patients with increased risk for vertebral fractures, especially those with rheumatoid arthritis (RA). Thus, prevention of GC-induced osteoporosis (GIOP) with bisphosphonates has now become an important strategy for reducing morbidity in RA patients. Ibandronate is indicated for the treatment and prevention of osteoporosis in postmenopausal women. However, evidence for ibandronate in GIOP prevention has been insufficient to date. Objectives To investigate efficacy of monthly ibandronate in RA women with reduced bone mineral density receiving long-term GCs Methods Female RA patients meeting the 1987 ACR classification criteria were enrolled in this 48-week double-blinded randomized placebo-controlled trial (clinicaltrials.gov NCT01287533). Patients that had taken GC (prednisolone-equivalent dose of ≥5 mg) for 3 or more consecutive months and fulfilling L1-4 T-score of < -1.0 and ≥ -2.5 by dual-energy X-ray absorptiometry were enrolled in this study. Patients were divided into 2 groups: 150 mg ibandronate versus placebo po every 4 weeks. Both groups were provided with daily 1500 mg of calcium carbonate and cholecalciferol of 400 IU. The primary end point was to compare the % changes of the L1-4 T-score at 48 weeks compared with baseline. Results Two hundred eleven patients from 13 centers nationwide participated in this study. One hundred sixty seven patients were randomized. The mean age of patients in the ibandronate and placebo group were 54.5 and 55.1 years, respectively. Baseline characteristics were not dissimilar between the 2 groups. The result of the primary endpoint is shown below (table). Serum C-terminal telopeptide was significantly reduced at 48 weeks in the ibandronate group. There was no incident of fracture in both groups during the study period. Safety profiles including adverse events were comparable between the 2 groups. Conclusions Monthly ibandronate for 48 weeks is effective in reducing bone loss in RA women on long-term glucocorticoids. Longer follow-up studies would be needed to investigate the effect on fracture prevention. Acknowledgements We would like to thank CTC bio for manufacturing the placebo, and Mr. Je-suk Kim for aiding statistical analyses. Disclosure of Interest None declared
    Annals of the Rheumatic Diseases 06/2015; 74(Suppl 2):762.1-762. DOI:10.1136/annrheumdis-2015-eular.3204 · 10.38 Impact Factor
  • Annals of the Rheumatic Diseases 06/2014; 73(Suppl 2):805-805. DOI:10.1136/annrheumdis-2014-eular.3438 · 10.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background CT-P13 is a biosimilar product of infliximab (INX). Data up to week 30 has been reported at EULAR 2012.1 Objectives To assess the PK, efficacy and safety of CT-P13 in patients with active AS up to week 54 and to compare this with INX, also in relation to the formation of anti-drug antibodies (ADAs). Methods Patients with active AS (1984 modified NY criteria) were randomised (1:1) to receive either CT-P13 (5mg/kg) or INX (5mg/kg) at weeks 0, 2, 6 and then every 8 weeks up to week 54. Results Of 250 patients randomised at baseline, 213 patients were treated up to week 54. Cmax of CT-P13 and INX were shown to be equivalent, since 90% CIs for the ratio of geometric means were within 80–125% at all doses (CT-P13, 128.1µg/mL–172.2µg/mL; INX, 123.0µg/mL–176.7µg/mL). At week 54, the proportion of patients testing positive for ADAs was comparable between CT-P13 and INX (22.9% [25/109] vs 26.7% [28/105]). ADAs had similar effects on PKs in both groups. Patients with negative ADA results had higher Cmax values (CT-P13, 134.5µg/mL–177.2µg/mL; INX, 131.9µg/mL–177.4µg/mL) compared with patients with positive results (CT-P13, 101.8µg/mL–160.4µg/mL; INX, 104.0µg/mL–175.2µg/mL). At week 54, ASAS40 and ASAS partial remission were comparable between groups (CT-P13, 54.7% and 19.8%; INX, 49.1% and 17.6%, respectively). More patients with negative ADA results achieved ASAS40 responses (CT-P13, 61.0%; IFX, 54.7%) compared with patients with positive results (CT-P13, 37.9%; IFX, 36.4%). The safety profiles of CT-P13 and INX were also comparable (table). Active tuberculosis (TB) was reported in 3 patients (CT-P13, 2; INX, 1) and there were no malignancies. Conclusions CT-P13 has similar PK values and a clinical efficacy comparable to INX up to week 54. CT-P13 was well tolerated with a safety profile comparable to that of INX up to 54 weeks. ADAs seem to diminish the clinical response to both agents in some patients. References Disclosure of Interest W. Park Consultant for: CELLTRION Inc., J. Jaworski Grant/research support from: CELLTRION Inc., J. Brzezicki Grant/research support from: CELLTRION Inc., A. Gnylorybov Grant/research support from: CELLTRION Inc., V. Kadinov Grant/research support from: CELLTRION Inc., I. Goecke Sariego Grant/research support from: CELLTRION Inc., C. Abud-Mendoza Grant/research support from: CELLTRION Inc., W. J. Otero Escalante Grant/research support from: CELLTRION Inc., S. W. Kang Grant/research support from: CELLTRION Inc., D. Andersone Grant/research support from: CELLTRION Inc., F. Blanco Grant/research support from: CELLTRION Inc., D. H. Yoo Consultant for: CELLTRION Inc., C. Ahn Consultant for: CELLTRION Inc., Speakers bureau: CELLTRION Inc., H. U. Kim Employee of: CELLTRION Inc., J. Braun Consultant for: CELLTRION Inc., Speakers bureau: CELLTRION Inc.
    Annals of the Rheumatic Diseases 01/2014; 72(Suppl 3):A516-A517. DOI:10.1136/annrheumdis-2013-eular.1548 · 10.38 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. Resveratrol is a naturally occurring polyphenol, which possesses chemotherapeutic potential through its ability to trigger apoptosis. The objective of this study was to investigate the major determinant for the apoptotic cell death induction by resveratrol in fibroblast-like synoviocytes (FLS) derived from patients with RA. Methods. The effect of resveratrol on apoptotic cell death was quantified in a population of subG1 in RA FLS by flow cytometry. The underlying signalling mechanism for apoptotic death was examined by analysing mitochondrial membrane potential, activation of the caspase cascade and translocation of Bid. Results. We show that activation of caspase-8 is essential for triggering resveratrol-induced apoptotic signalling via the involvement of the mitochondrial pathway in RA FLS. Our findings also suggest that this enhanced apoptosis caused by resveratrol occurred in RA FLS irrespective of p53 status. Exposure to resveratrol caused extensive apoptotic cell death, along with a caspase-dependent (activation of caspase-9 and -3, poly ADPribose polymerase (PARP) cleavage and mitochondrial cytochrome c release) or caspase-independent (translocation of apoptosis-inducing factor (AIF) to the nucleus) signalling pathway. Analysis of upstream signalling events affected by resveratrol revealed that the activated caspase-8 triggered mitochondrial apoptotic events by inducing Bid cleavage without any alteration in the levels of Bax, Bcl-xL or Bcl2. The caspase-8 inhibitor or over-expression of crmA abrogated cell death induced by resveratrol and prevented processing of the downstream cascade. Conclusion. The results suggest that resveratrol causes activation of caspase-8, which in turn results in modulation of mitochondrial apoptotic machinery to promote apoptosis of RA FLS.
    Rheumatology (Oxford, England) 11/2007; 47(3):301-308. DOI:10.1093/rheumatology/kem368 · 4.48 Impact Factor
  • YJ Lee · S W Kang · J K Song · J J Park · YD Bae · E Y Lee · E B Lee · Y W Song
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the serum levels of galectin-3 (Gal-3) and galectin-3 binding protein (G3BP) and to evaluate the associations between clinical features and these levels in patients with Behçet's disease (BD). Fifty patients with BD (mean age 40.6 +/- SEM 1.4 years; 21 males, 29 females; 26 active and 24 inactive patients), 20 patients with rheumatoid arthritis (RA), and 20 patients with systemic lupus erythematosus (SLE) were enrolled. Clinical features of BD patients including BD activity and severity over the previous 4 weeks were reviewed and serum levels of Gal-3 and G3BP were determined using enzyme-linked immunosorbent assays (ELISA). Serum Gal-3 levels were significantly higher in total BD patients than in healthy controls (mean +/- SEM, 10.68 +/- 0.93 versus 7.59 +/- 0.48 ng/mL; p = 0.0042 by Student's t-test), and active BD patients had significantly higher levels of serum Gal-3 than inactive patients and controls (13.08 +/- 1.53 in active BD, 8.08 +/- 0.71 ng/mL in inactive BD; p = 0.000039 by one way ANOVA). Although mean G3BP serum levels were not different in total BD patients and controls, active BD patients (6806.63 +/- 468.58 ng/mL) had higher G3BP levels than controls (5421.05 +/- 286.02 ng/mL; p = 0.031 by one way ANOVA). Additionally, serum Gal-3 significantly increased in patients with RA (p = 0.019 by t-test) and SLE (p = 0.00069) and G3BP increased in patients with SLE (p = 0.000012), compared to those in healthy controls. When we analyzed for associations with clinical features over the previous 4 weeks, Gal-3 was associated with orogenital ulcers (p = 0.036 by t-test) and time elapsed from symptom onset (p = 0.032, Pearson's coefficient = 0.314). Serum concentrations of Gal-3 (p = 0.013) and G3BP (p = 0.032) were positively correlated with the BD severity score for the previous 4 weeks. Gal-3 levels were significantly correlated with TNF-alpha (p = 0.048, Pearson's coefficient = 0.281) and G3BP levels were correlated with levels of C-reactive protein (p = 0.021, Pearson's coefficient = 0.329) in total BD patients. In multivariate analysis of all cytokines levels, only Gal-3 was significantly related to BD activity or severity for the previous 4 weeks. These results suggest that serum levels of Gal-3 and G3BP are increased in active BD patients and Gal-3 can be a new biomarker indicating disease activity in BD although their increments are not disease-specific.
    Clinical and experimental rheumatology 11/2006; 25(4 Suppl 45):S41-5. · 2.72 Impact Factor
  • Source
    H J Baek · S W Kang · Y J Lee · K C Shin · E B Lee · C D Yoo · Y W Song
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated the frequency and distribution of osteopenia according to the clinical severity in ankylosing spondylitis (AS). Bone mass was measured in men with mild (n = 45) and severe AS (n = 31) with dual-energy X-ray absorptiometry (DEXA). Definition of clinical severity was based on the Schober's test. Osteopenia was commonly detected (48% in mild AS and 39% severe AS) and, in mild disease, more frequently observed at the lumbar spine than any of the proximal femur sites. In severe AS, however, the frequency of osteopenia at the femoral neck and Ward's triangle was as high as at the lumbar spine. Both bone mineral density and T-scores in severe disease were lower than in mild disease at the femur neck, Ward's triangle, and total proximal femur, but not in the lumbar spine. The progression of osteopenia may be reflected more reliably at proximal femur sites than at the lumbar spine.
    Rheumatology International 12/2005; 26(1):30-4. DOI:10.1007/s00296-004-0516-3 · 1.52 Impact Factor
  • Source
    H J Baek · K C Shin · YJ Lee · S W Kang · E B Lee · C D Yoo · YW Song
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated the clinical features of Korean patients with adult-onset ankylosing spondylitis (AAS) and examined the differences between AAS patients with and without peripheral joint disease (PJD). We studied 67 consecutive patients with primary AAS who visited the rheumatology clinic of a tertiary referral hospital. All patients experienced joint symptoms after the age of 15 and fulfilled the modified New York criteria for ankylosing spondylitis. Hips and shoulders were not considered as peripheral joints. The male-to-female ratio was 8.6:1.0. Mean age at disease onset was 22.3 +/- 5.5 (mean +/- s.d.) yr and disease duration was 10.8 +/- 8.0 yr. Spinal symptoms were the first manifestations in 80.6% of patients. During the disease course, hip, shoulder and peripheral joint involvement were found in about 60% of patients. In patients with PJD, the most commonly affected joints were the knees and ankles. The pattern of PJD, in most cases, was asymmetrical and mono/oligoarticular. AAS patients with PJD had fewer spinal symptoms than those without PJD as a presenting feature (71.8 vs 92.9%, P = 0.035). The modified Schober test showed greater increments in patients with PJD (4.9 +/- 2.4 vs 3.0 +/- 2.4 cm, P = 0.002). Forced vital capacity was better in patients with PJD (79.0 +/- 11.4 vs 70.8 +/- 15.5% of predicted value, P = 0.016). Totally ankylosed sacroiliitis, spinal squaring and syndesmophytes on radiographs were less common in the patients with PJD than in those without PJD (33.3 vs 64.2%, P = 0.012; 20.5 vs 67.9%, P = 0.000; and 38.5 vs 71.4%, P = 0.008, respectively). Peripheral joints as well as shoulder and hip joints were more frequently involved during the disease course in Korean AAS patients compared with earlier reports in Caucasians. The general joint involvement pattern of PJD was similar to patterns reported previously. Our data suggest that, clinically and radiographically, AAS patients with PJD have a less severe spinal disease course than those without PJD.
    Rheumatology 01/2005; 43(12):1526-31. DOI:10.1093/rheumatology/keh373 · 4.48 Impact Factor
  • Source
    Y J Lee · K S Shin · S W Kang · C K Lee · B Yoo · H S Cha · E M Koh · S J Yoon · J Lee
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the genetic influence of PvuII and XbaI polymorphisms of oestrogen receptor alpha (ORalpha) in patients with systemic lupus erythematosus (SLE) in Korea. Genomic DNA from 268 female controls and 137 female SLE patients (41 childhood onset and 96 adult onset) were analysed using PvuII and XbaI restriction fragment length polymorphism. Comparison of the frequencies of alleles and genotypes was made in control and patient groups and in childhood onset and adult onset SLE subgroups. Although the Pp genotype occurred more often in SLE patients than in controls (p(c) = 0.017), ORalpha genotype distributions of adult onset SLE did not differ significantly from controls. The PP, Pp, and xx genotypes occurred less often in childhood onset SLE (p(c) = 0.0045, 0.0498, and 0.0255, respectively) than in controls. Additionally, the PP genotype was less common in childhood onset than in adult onset SLE (p(c) = 0.016). SLE patients with the PP genotypes were older at disease onset than those with the other genotypes (p = 0.001). Patients with the Xx genotype had an earlier onset of SLE than those with the xx genotype (p = 0.025). The frequency of the combined ppXx genotype was greater in childhood onset SLE than in controls (p(c) = 0.0009) or adult onset SLE (p(c) = 0.027). The same trend was supported by subgroup analyses according to age at menarche and logistic multivariate analyses. ORalpha polymorphisms are significantly associated with the age at disease onset in Koreans with SLE.
    Annals of the Rheumatic Diseases 11/2004; 63(10):1244-9. DOI:10.1136/ard.2003.012583 · 10.38 Impact Factor
  • Source
    K C Shin · Y J Lee · S W Kang · H J Baek · E B Lee · H A Kim · Y W Song
    Annals of the Rheumatic Diseases 11/2001; 60(10):988-9. · 10.38 Impact Factor
  • Y J Lee · K C Shin · S W Kang · E B Lee · H A Kim · Y W Song
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the blood concentration of type III procollagen N-terminal propeptide (PIIINP), soluble interleukin-2 receptor (sIL-2R), and von Willebrand factor (vWF) in systemic sclerosis (SSc) patients. PIIINP, sIL-2R, and vWF were measured in the sera and plasma of 29 SSc patients and 29 sex- and age-matched healthy controls. Serum PIIINP was determined by radioimmunoassay. Both serum sIL-2R and plasma vWF were measured by enzyme-linked immunosorbent assay (ELISA). Associations between concentrations and clinical and laboratory features were evaluated. Serum levels of PIIINP and sIL-2R were significantly higher in the SSc group than in the control group (p < 0.01 for both). No differences in serum PIIINP and sIL-2R levels were found between the limited and diffuse cutaneous subsets. However, PIIINP concentrations were significantly higher in anti-Scl-70 positive SSc patients compared with those of anti-Scl-70 negative patients (p = 0.01). Serum PIIINP levels were significantly higher in SSc patients with restrictive pulmonary function (FVC < 80%) than in patients with normal pulmonary function (p < 0.05). The correlation between PIIINP levels and FVC (p < 0.05) was negative, but the correlation between PIIINP levels and modified Rodnan skin scores (p < 0.05) was positive. sIL-2R levels were not correlated with skin and pulmonary involvement of SSc. There was no difference in vWF levels between those of the SSc patients and those of the control groups. These results suggest that serum PIIINP serves as a biologic marker for the extent of skin and pulmonary involvement in systemic sclerosis. Increased serum levels of sIL-2R in SSc patients support a role for T lymphocyte activation in the pathogenesis of systemic sclerosis.
    Clinical and experimental rheumatology 01/2001; 19(1):69-74. · 2.72 Impact Factor
  • H J Baek · K C Shin · Y J Lee · S W Kang · E B Lee · Y W Song
    [Show abstract] [Hide abstract]
    ABSTRACT: Marfan syndrome (MS) is a dominantly inherited connective tissue disorder characterized by arachnodactyly, tall stature, the presence of aortic aneurysm, and lens dislocation. Takayasu's arteritis (TA) is a chronic vasculitis that primarily affects the aorta and its branches. The authors report the first case of TA in a patient with MS. The simultaneous presence of TA and MS could be a coincidence, however; the pathogenesis of TA might be linked with autoimmunity induced by abnormal extracellular matrix protein derived from the genetic mutations in MS.
    Angiology 06/2000; 51(5):435-9. · 2.97 Impact Factor
  • S W Kang · E B Lee · H J Baek · H A Kim · B L Chang · Y W Song
    Clinical and experimental rheumatology 01/1999; 17(5):635-6. · 2.72 Impact Factor

Publication Stats

160 Citations
73.49 Total Impact Points


  • 2015
    • Chungnam National University Hospital
      Sŏul, Seoul, South Korea
  • 2007
    • Chungnam National University
      • Department of Internal Medicine
      Daiden, Daejeon, South Korea
  • 2006
    • Seoul Medical Center
      Sŏul, Seoul, South Korea
  • 2005
    • Seoul National University Hospital
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea